Cytokinetics, Inc. Annual Shareholder Meeting
May 15, 2019 10:30 AM PDT
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>
Clinical Trial Enrolled Over 8,200 Patients With Reduced Ejection Fraction in 35 Countries SOUTH SAN FRANCISCO, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in GALACTIC-HF ( G lobal A pproach to L owering A
Two Studies Show Addition of Reldesemtiv to SMN-Directed Treatment Increases Muscle Force in Mouse Model of Spinal Muscular Atrophy SOUTH SAN FRANCISCO, Calif. , June 28, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from two preclinical studies of
SOUTH SAN FRANCISCO, Calif. , June 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that two preclinical poster presentations on the addition of reldesemtiv to treatment with SMN upregulators ( nusinersen and SMN-C1, an analogue to risdiplam ) will be presented
SOUTH SAN FRANCISCO, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19,
